Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis

• Published in: Pediatric Rheumatology 2021-04, Vol.19 (1), p.49-49, Article 49
• Main Authors: Chi, Ying, Liu, Rong, Zhou, Zhi-Xuan, Shi, Xiao-Dong, Ding, Yu-Chuan, Li, Jian-Guo
• Format: Article
• Language: English
• Subjects: Age; Analysis; Arthritis; Children; Connective tissue diseases; Cytokines; Cytomegalovirus; Dexamethasone; Enzymes; Epstein-Barr virus; Etoposide; Health aspects; Hemoglobin; Hemophagocytic lymphohistiocytosis; Infections; Janus kinase inhibitor; Kinases; Laboratories; Liver; Lymphatic diseases; Methylprednisolone; Normal distribution; Pediatrics; Political activity; Political aspects; Rheumatoid arthritis; Ruxolitinib; Statistical analysis; Tuberculosis; Viral infections
• ISSN: 1546-0096; 1546-0096
• DOI: 10.1186/s12969-021-00534-0

This study aimed to analyze the effects of ruxolitinib on children with secondary hemophagocytic lymphohistiocytosis (HLH). Eleven pediatric patients diagnosed with HLH and treated with ruxolitinib (ruxolitinib group: group R) between November 2017 and August 2018 were retrospectively analyzed. Eleven age-matched pediatric patients with HLH undergoing conventional treatment (control group: group C) during the same period were also analyzed. In group R, three patients who did not respond to methylprednisolone (MP) pulse and intravenous immunoglobulin (IVIG) therapies were treated with Ruxolitinib and their temperature decreased to normal levels. Four patients had normal temperature after conventional treatment (dexamethasone and etoposide, with or without cyclosporine A), but they had severe organ involvement, including obvious yellowing of the skin, increased liver enzyme levels and neuropsychiatric symptoms, and they were all ameliorated with ruxolitinib treatment. Four patients were relieved with ruxolitinib therapy alone. In group C, the body temperatures of eleven patients decreased to normal levels after conventional treatment. The body temperature of group R patients decreased to normal levels more rapidly than that of group C patients. The glucocorticoid dosage in group R was significantly lower than that in group C. Both groups were followed-up for 2-2.5 years. No obvious adverse drug reactions to ruxolitinib were observed during treatment and follow-up. Ruxolitinib might be an effective drug in controlling body temperature and reducing inflammation indicators. It might be a potential replacement for glucocorticoid therapy for HLH treatment in children, thereby reducing or avoiding glucocorticoid-related adverse reactions.